Eiger BioPharmaceuticals, Inc.
eigerbio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2023 10-K, filed Apr 8, 2024. Its latest SEC filing is a 15-12G from Oct 1, 2024.
10-K for FY2023, filed Apr 8, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Sells Zokinvy, a treatment for progeria, and develops drug candidates for patients with hepatitis delta and rare metabolic diseases.
10-K for FY2023, filed Apr 8, 2024
How Did They Make Money?
Eiger earns money by selling Zokinvy to specialty pharmacies and distributors; a sale counts when the product is delivered.
10-K for FY2023, filed Apr 8, 2024The Company’s product revenue consists of sales of Zokinvy, which received FDA approval in November 2020 and was launched commercially in…View ↗
In June 2021, the French National Agency for Medicines and Health Products Safety (ANSM) granted Zokinvy (lonafarnib) a Temporary…View ↗
The Company recognizes product revenue when a customer obtains control of its product, which occurs at a point in time, typically upon…View ↗
-
10-K for FY2023, filed Apr 8, 2024
FY2023 revenue by product or service ↗
$15.8M
-
10-K for FY2023, filed Apr 9, 2024
$15.8M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
10-K for FY2023, filed Apr 8, 2024 |
98% |
Product revenue, net, FY2023
$15.5M Sources
|
Sold outright |
|
Other revenue
|
1.6% |
Other revenue, FY2023
$250K Sources
|
Who Were Their Customers?
In the U.S., it sells Zokinvy to a specialty pharmacy that dispenses directly to patients. In France, it sells through a distributor that ships to pharmacies after receiving physician requests.
10-K for FY2023, filed Apr 8, 2024
Did Revenues Turn Into Profits?
No. It lost $75M in FY2023.
10-K for FY2023, filed Apr 9, 2024
−$71.8MView ↗
10-K for FY2023, filed Apr 9, 2024
−$75MView ↗
10-K for FY2023, filed Apr 9, 2024
−$74.8MView ↗
How Were They Changing?
-
Oct 1, 2024
Liquidation plan took effect and common shares were cancelled
Existing equity holders may receive a pro rata share of the recovery pool, if any.
Sources
8-K, filed Oct 1, 2024
As previously disclosed, on September 5, 2024, the Bankruptcy Court entered an order (the “Confirmation Order”) confirming the Fifth…View ↗
-
Sep 9, 2024
Bankruptcy court approved the sale of Zokinvy assets to Sentynl
Sources
8-K, filed Sep 9, 2024
obtained, on April 24, 2024, the Order (I) Approving the Sale of the Debtors’ Zokinvy Assets, (II) Authorizing Assumption and Assignment of…View ↗
-
Sep 4, 2024
Lonafarnib antiviral and lambda assets were sold
Sources
8-K, filed Sep 4, 2024
The sale of the Company’s lonafarnib antiviral asset closed on September 3, 2024. Under the terms of the sale, the Purchaser acquired the…View ↗
-
Jul 10, 2024
Avexitide assets were sold to Amylyx
Sources
8-K, filed Jul 10, 2024
On June 17, 2024, following the completion of the auction held as part of the Company’s court-supervised sale process under Section 363 of…View ↗
Portfolio focus
The portfolio emphasis moved from HDV development to avexitide for hyperinsulinemic hypoglycemia, while the company continued selling Zokinvy and evaluated partnerships for its virology assets.
10-K for FY2020, filed Mar 9, 2021 10-K for FY2023, filed Apr 8, 2024We are a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for…View ↗
We are developing two complementary treatments for HDV. Lonafarnib is a first-in-class, oral farnesylation inhibitor in a global Phase 3…View ↗
Avexitide in Congenital Hyperinsulinism (CHI)View ↗
In June 2023, in connection with an extensive portfolio prioritization review, we announced that the Company is focusing its clinical…View ↗
In June 2023, in connection with an extensive portfolio prioritization review, we announced that the Company is focusing its clinical…View ↗
We continue to evaluate strategic partnering options for our virology assets: lonafarnib, a first-in-class, oral prenylation inhibitor for…View ↗
Zokinvy sales
Zokinvy moved from an approved product to commercial sales in the U.S. and Europe.
10-K for FY2020, filed Mar 9, 2021 10-K for FY2023, filed Apr 8, 2024The FDA approved our first commercial product, Zokinvy (lonafarnib) to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome…View ↗
Who Did They Compete With?
Competes with Gilead, Vir, Janssen Research & Development, Replicor, PharmaEssentia, Albireo, Assembly, PRG Science & Technology, Zealand Pharmaceuticals, Rezolute, Hamni, Recordati, Vogenyx, and MBX
10-K for FY2023, filed Apr 8, 2024HDV: Gilead (conditional approval in Europe, BLA submitted in the U.S.), Vir (Phase 2), Janssen Research & Development, LLC (Phase 2)…View ↗
Loading...
